Product Name: PIM1 (160-181)
Product Number: PE-01AQM80
| Size: | 1 mg | Price: | 120.00 | |
| 5 mg | $US | 260.00 | ||
| 20 mg | 460.00 |
Peptide Name: PIM1 (160-181)
Product Use: Services as a blocking peptide for use with the Pim1-III rabbit polyclonal antibody (Cat. No.: AB-NK258-1) that is also available from Kinexus. The peptide sequence is located in the kinase catalytic subdomain 3.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: VEKDRISDWGELPNGTRVPMEVGGC
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 2744.02 Da
Peptide Purity Percent after Synthesis and Purification: >80
Product Use: Services as a blocking peptide for use with the Pim1-III rabbit polyclonal antibody (Cat. No.: AB-NK258-1) that is also available from Kinexus. The peptide sequence is located in the kinase catalytic subdomain 3.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: VEKDRISDWGELPNGTRVPMEVGGC
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 2744.02 Da
Peptide Purity Percent after Synthesis and Purification: >80
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: PIM1 pan-specific antibody (Cat. No.: AB-NK258-1)
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: PIM1 pan-specific antibody (Cat. No.: AB-NK258-1)
Scientific Background: Pim1 is a protein-serine/threonine kinase of the CAMK group and PIM family. The expression of Pim1 in normal tissues is almost undetectable, but it is widely distributed in most tested human tissues. Its expression can be stimulated by a variety of growth factors and is regulated at four different levels: transcriptional, post-transcriptional, translational and post-translational. Expression of Pim1 is mediated through activation of the JAK/STAT pathway. Pim1 is activated by phosphorylation at S280 and Y309 (by Etk). Pim1 is involved in the control of cytokine-mediated cell proliferation, differentiation and survival of lymphoid and myeloid cells as well as others. Pim1 was originally identified as a transduced oncogene from Moloney murine leukemia virus induced T-cell lymphomas in mice. The Pim1 protein is undergoes relatively little mutation in human tumours, about the same as typical proteins. The oncogenic activity of the Pim-1 protein is mediated through the positive regulation of Myc transcription, the regulation of cell cycle progression, and by the inhibition of the pro-apoptotic proteins BAD, MAP3K5, and FOXO3. In addition, Pim-1 has been shown to promote genomic instability. Gain-of-function mutations in the Pim-1 gene resulting in the up-regulation of Pim-1 activity have been observed in several human cancer types, indicating a role in tumourigenesis. For example, significantly elevated Pim-1 expression was observed in several hematopoietic malignancies and in several solid tumours. In animal studies, over-expression of the Pim-1 protein in mice leads to an increased occurence of tumours, while the knockout of Pim-1 expression has no observable phenotypic consequence. Pim1 has been linked with the development of prostate cancer, colorectal adenocarcinomas, large-cell lymphomas and hematopoietic malignancies.
© Kinexus Bioinformatics Corporation 2017